1006 related articles for article (PubMed ID: 18400077)
21. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
[TBL] [Abstract][Full Text] [Related]
23. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
[TBL] [Abstract][Full Text] [Related]
24. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease.
Osborn MK; Guest JL; Rimland D
HIV Med; 2007 Jul; 8(5):271-9. PubMed ID: 17561872
[TBL] [Abstract][Full Text] [Related]
26. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
27. Influence of viral hepatitis on HIV infection.
Rockstroh JK
J Hepatol; 2006; 44(1 Suppl):S25-7. PubMed ID: 16338020
[TBL] [Abstract][Full Text] [Related]
28. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?
Jain MK; Opio CK; Osuagwu CC; Pillai R; Keiser P; Lee WM
Clin Infect Dis; 2007 Apr; 44(7):996-1000. PubMed ID: 17342656
[TBL] [Abstract][Full Text] [Related]
29. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC
Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088
[TBL] [Abstract][Full Text] [Related]
30. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
[TBL] [Abstract][Full Text] [Related]
31. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort.
Bloquel B; Jeulin H; Burty C; Letranchant L; Rabaud C; Venard V
J Med Virol; 2010 Feb; 82(2):206-12. PubMed ID: 20029819
[TBL] [Abstract][Full Text] [Related]
32. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
Kumar R; Singla V; Kacharya Sk
Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
[TBL] [Abstract][Full Text] [Related]
33. Outcome and prognosis factors in HIV-infected hemodialysis patients.
Tourret J; Tostivint I; du Montcel ST; Bragg-Gresham J; Karie S; Vigneau C; Guiard-Schmid JB; Deray G; Bagnis CI
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1241-7. PubMed ID: 17699354
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
[TBL] [Abstract][Full Text] [Related]
35. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.
Matthews GV; Manzini P; Hu Z; Khabo P; Maja P; Matchaba G; Sangweni P; Metcalf J; Pool N; Orsega S; Emery S;
AIDS; 2011 Sep; 25(14):1727-35. PubMed ID: 21716078
[TBL] [Abstract][Full Text] [Related]
36. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
37. Treatment of chronic hepatitis B in HIV co-infected patients.
Guan R
Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
[TBL] [Abstract][Full Text] [Related]
38. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.
Filippini P; Coppola N; Pisapia R; Scolastico C; Marrocco C; Zaccariello A; Nacca C; Sagnelli C; De Stefano G; Ferraro T; De Stefano C; Sagnelli E
AIDS; 2006 Jun; 20(9):1253-60. PubMed ID: 16816553
[TBL] [Abstract][Full Text] [Related]
39. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
[TBL] [Abstract][Full Text] [Related]
40. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.
Lohse N; Ladefoged K; Pedersen L; Jensen-Fangel S; Sørensen HT; Obel N
Scand J Infect Dis; 2004; 36(10):738-42. PubMed ID: 15513400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
